Arginox Pharmaceuticals has announced that the 50 percent patient enrollment target has been achieved in its pivotal, Phase III, registration study of tilarginine acetate injection in patients experiencing cardiogenic shock following reperfusion for acute myocardial infarction.
Cardiogenic shock is the most common cause of death among patients who are hospitalized with an acute myocardial infarction. The TRIUMPH trial is evaluating the safety and efficacy of tilarginine in reducing 30-day mortality in 658 cardiogenic shock patients at over 130 sites in the U.S., Canada, and Europe.
